About CathWorks
CathWorks is a medical technology company that leverages artificial intelligence (AI) and advanced computational science to transform the diagnosis and treatment of cardiovascular disease. Their flagship product, the FFRangio System, provides physicians with objective, wire-free fractional flow reserve (FFR) guidance derived from routine angiograms. This system eliminates the need for invasive pressure wires and drug-induced hyperemia traditionally required for FFR measurements, offering a quicker and more practical solution for assessing coronary artery disease (CAD) during catheterization procedures.
For physicians, the FFRangio System aims to optimize percutaneous coronary intervention (PCI) therapy decisions by providing comprehensive physiological information and color-coded 3D renderings of blood flow in the coronary arteries. This allows for more accurate treatment planning, including determining the necessity of a stent. The technology is designed to integrate seamlessly into existing cath lab workflows, enhancing efficiency and potentially improving patient outcomes by enabling evidence-based decision-making.
Focus Areas
Business Intelligence
| Technology | AI and advanced computational science platform that transforms routine angiogram images into 3D models of coronary arteries to provide FFRangio values. It leverages a resistance-based computational approach. |
What Physicians Need to Know
For physicians, CathWorks' FFRangio® System offers several key advantages. It provides comprehensive, real-time physiological assessment of the entire coronary tree without the need for invasive pressure wires or hyperemic drugs, reducing patient risk and radiation exposure. The AI-powered analysis and 3D modeling optimize clinical decision-making by offering detailed insights into lesion significance and supporting PCI planning. This can lead to more precise and individualized treatment approaches, improved workflow efficiency, and potentially better patient outcomes. The system has demonstrated high diagnostic accuracy compared to wire-based FFR.
The CathWorks FFRangio® System is designed for seamless integration with existing cath lab infrastructure, including the boom and PACS (Picture Archiving and Communication System). It analyzes previously acquired angiography DICOM data, making it compatible with routine angiogram procedures. CathWorks was acquired by Medtronic in 2026, further expanding its reach and integration within interventional cardiology portfolios.
What the Web Says
CathWorks appears to be a company with a promising product, the FFRangio system, which is generally well-received by healthcare professionals for its potential to improve cardiac care. However, internal company reviews suggest a mixed to negative sentiment regarding management, work-life balance, and company culture, with some employees expressing concerns about leadership and high turnover.
Overall: MixedStrengths
- Innovative product (FFRangio) with potential to improve patient outcomes
- Strong clinical data supporting product efficacy
- Positive impact on cardiac care procedures
- Opportunity to work with cutting-edge technology
- Dedicated and passionate colleagues (product-focused)
- Good benefits package (mentioned in some employer reviews)
Limitations
- Concerns about management and leadership decisions
- Issues with work-life balance and long hours
- High employee turnover reported by some
- Lack of clear communication from upper management
- Internal culture issues and perceived micromanagement
- Rapid growth leading to organizational challenges
Based on reviews from: Glassdoor, Reddit (healthcare professional discussions), Healthcare IT review sites (general industry sentiment), Clinical trial publications/presentations
Last updated: 2026-10-23
Videos
News, demos, and interviews about CathWorks.
Videos load interactively. If none appear, search YouTube for CathWorks →
Press & Coverage
Frequently Asked Questions
Investors
Who's funded CathWorks.
Related Companies
Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]
SOPHiA GENETICS is a healthcare AI company that has developed a cloud-native, AI-driven SaaS platform called SOPHiA DDM™. This platform is designed to enable hospitals, clinical laboratories, academic medical centers, and biopharmaceutical companies to analyze and interpret complex genomic, radiomic, and multimodal healthcare data. The company’s mission is to democratize data-driven medicine, providing actionable insights […]
Qure.ai is a leading healthcare AI company that leverages deep learning and artificial intelligence to revolutionize medical imaging diagnostics and make healthcare more accessible and affordable globally. The company develops AI-powered solutions for interpreting X-rays and CT scans, addressing critical health needs in areas such as lung, musculoskeletal, cardiovascular, and neurocritical health. Their technology assists […]
Deep Bio is a healthcare AI company that develops deep learning-based cancer diagnostic support software, aiming to advance patient outcomes by empowering clinicians with innovative technology. Their mission is to provide tools that enable medical professionals to make critical decisions, ultimately enhancing healthcare delivery and allowing clinicians to focus more on patient care. The company’s […]
CortiCare is a healthcare AI company specializing in neuro telemetry and remote patient monitoring, primarily focusing on electroencephalogram (EEG) services. The company provides telehealth services and an EEG brain monitoring platform to neurology and critical care areas within hospitals, including ICUs, NICUs, PICUs, and EMUs. Their services aim to enhance the neurological assessment of adult, […]
CapsoVision is a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (AI) technologies for capsule endoscopy solutions. Their primary goal is to identify abnormalities of the gastrointestinal (GI) tract for diagnostic and screening purposes. [7] Their flagship product, the CapsoCam Plus system, is a single-use capsule endoscope equipped with four cameras, providing […]